Stay updated with breaking news from Davidm Urso. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
SAN DIEGO--(BUSINESS WIRE)--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corpor...
MEI Pharma, Inc. , a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the...
– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target...
Commits to Capital Return of Up to $3.15 per Share Adds Three New Directors and Forms Capital Allocation Committee of the Board ...
File New Definitive Consent Materials to Remove Entire MEI Pharma Board for Cause and Add Advisory Proposal Requesting the Return of Capital to...